

Adnavance Technologies Inc. Appoints BioSite Co-Founder Kenneth Buechler, Ph.D., to its Board of Directors

April 10, 2008 - - VANCOUVER, British Columbia & SAN DIEGO - - Adnavance Technologies Inc., a developer of direct detection molecular diagnostic tests for medical applications, announced today that it has appointed Kenneth Buechler, Ph.D., to its Board of Directors. Dr. Buechler was a co-founder of BioSite and served as the Company's president until it was sold to Inverness for \$1.9B last July.

"We are very pleased to have Ken join our Board as an independent director," said Vincent Lum, Chairman of the Board. "As a co-founder of BioSite, Ken has first-hand experience in the development and commercialization of diagnostic technology. His knowledge of the regulatory process, market development and strategic partnering will be invaluable as we continue to develop our direct detection molecular diagnostic platform."

Adnavance Technologies Inc. has developed a proprietary ultra-sensitive DNA detection platform that may eliminate the need for amplification. The Company's ultra-sensitive technology provides a range of significant advantages over existing DNA testing methods, including ease of use, time to result, lower cost.

"New technologies always open new markets, and the Adnavance M-DNA platform represents an opportunity to diversify the molecular diagnostic testing market," said Dr. Buechler. "M-DNA is enabling, simple, fast, ultra-sensitive and cost effective. I'm excited to join the Board and help further the development of this important medical technology."

Adnavance is initially focusing on the U.S. market where it believes its platform technology will de-centralize molecular testing and open the market to approximately 30,000 new customers who are currently not licensed to perform medical tests. It is expected that the Company's technology will create a significant marketing gateway to enable significant growth in the existing \$2.2 billion molecular diagnostic marketplace.

"Ken brings the experience we need at this stage of our development," said Randy White, Adnavance CEO. "He understands how to finance early stage companies, how to navigate the FDA and most importantly how to develop markets and successfully introduce new products. We are very pleased to have him join the Board."

About Adnavance Technologies Inc.

Adnavance is a molecular diagnostic company focused on development of DNA-based tests using the Company's patented Metalized-DNA (MDNA) platform. The Company is headquartered in Vancouver, British Columbia and also maintains a DNA development laboratory in San Diego, CA. MDNA is based on the conducting properties of hybridized DNA. Under strict reaction conditions, certain metal ions can enter the central core of hybridized DNA and displace the hydrogen bonds forming the equivalent of a metal wire in the center of the DNA and making the DNA highly conductive. The Company uses a microarray of 10-micron electrodes to detect the MDNA and the inherent ultra-sensitivity arises from the differential change in conductivity between hybridized DNA and Metalized DNA. This change in conductivity is so large that it obviates the need for target amplification used in current molecular-based tests. Adnavance scientists were the first to discover the MDNA phenomenon,

and the Company believes its technology platform will open new molecular testing markets. For additional information please see the Company website at www.adnavance.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as “expect,” “should,” “anticipate,” and similar words indicating uncertainty in facts and figures. Although Adnavance believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. Actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with the technology development process, the risk that Adnavance technology will not gain market acceptance, the risks associated with dependence upon key personnel and the need for additional financing to commercialize the technology platform.